<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02921217</url>
  </required_header>
  <id_info>
    <org_study_id>BIFFAT</org_study_id>
    <nct_id>NCT02921217</nct_id>
  </id_info>
  <brief_title>Effect of a Probiotic on Visceral Fat Accumulation</brief_title>
  <acronym>BIFFAT</acronym>
  <official_title>Randomized, Parallel, Double Blinded, Placebo-controlled Study for the Evaluation of the Effectiveness on Visceral Fat Accumulation in Individuals With Abdominal Obesity of a Specific Probiotic Compound</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biopolis S.L.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Technological Centre of Nutrition and Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Universitari Sant Joan de Reus</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Rovira i Virgili</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Biopolis S.L.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study's main objective is to investigate if an extract containing the probiotic
      Bifidobacterium animalis subsp. lactis BPL1 (CECT 8145) has a positive effect on the
      accumulation of abdominal visceral fat in people with abdominal obesity.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study's main objective is to investigate if an extract containing the probiotic
      Bifidobacterium animalis subsp. lactis BPL1 (CECT 8145) has a positive effect on the
      accumulation of abdominal visceral fat in people with abdominal obesity.

      Participants: 129 men and women with a waist circumference ≥102 cm (men) or ≥88 cm (women),
      randomly assigned to one of 3 treatment groups in parallel: one group (43 members) with
      active probiotic, another one with the probiotic inactivated by heat, and the last group with
      the placebo.

      Treatment consists of product consumption study for 12 weeks, taking 1 capsule per day. 4
      visits during the study, a pre-inclusion visit and 3 study visits (weeks 1, 6, and 12) will
      be scheduled.

      Secondary objectives are to asses the probiotic's effects on:

        -  the accumulation of subcutaneous body fat and body weight, body mass index (BMI) and
           waist circumference.

        -  glucose metabolism and insulin resistance.

        -  blood lipid profile.

        -  blood pressure.

        -  inflammation.

        -  circulating levels of adiponectin and leptin.

        -  changes in the intestinal microbiome

      The statistical analysis will follow the principles specified in the guidelines of the ICHE9
      and CPMP/EWP/908/99 ICHE9 Points to Consider on Multiplicity Issues in Clinical Trials.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2016</start_date>
  <completion_date type="Anticipated">August 2017</completion_date>
  <primary_completion_date type="Anticipated">May 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of abdominal visceral fat</measure>
    <time_frame>Change from 0 weeks (V1) to 12 weeks (V3)</time_frame>
    <description>abdominal visceral fat will be measured by Nuclear Magnetic Resonance (NMR). The study will be conducted in 3 Teslas MRI (Signa LX Echo Speed Plus Excite, General Electric, Milwaukee, WI).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change of body weight</measure>
    <time_frame>Change from 0 weeks (V1) to 6 weeks (V2), and to 12 weeks (V3)</time_frame>
    <description>Body weight measured with Tanita TBF-300 (Body Composition Analyzer, Brooklyn NY, USA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of BMI</measure>
    <time_frame>Change from 0 weeks (V1) to 6 weeks (V2), and to 12 weeks (V3)</time_frame>
    <description>Calculated using weight and height. Body weight measured with Tanita TBF-300 (Body Composition Analyzer, Brooklyn NY, USA). Height, measured by Tanita portable altimeter; BMI calculated (kg/m2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Waist circumference</measure>
    <time_frame>Change from 0 weeks (V1) to 6 weeks (V2), and to 12 weeks (V3)</time_frame>
    <description>Waist circumference, measured according to the criteria of Lohman et al. 1988.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Abdominal subcutaneous fat</measure>
    <time_frame>Change from 0 weeks (V1) to 12 weeks (V3)</time_frame>
    <description>Abdominal subcutaneous fat measured by 3 Teslas MRI (Signa LX Echo Speed Plus Excite, General Electric, Milwaukee, WI).</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">129</enrollment>
  <condition>Obesity</condition>
  <condition>Intra-Abdominal Fat</condition>
  <condition>Subcutaneous Fat, Abdominal</condition>
  <arm_group>
    <arm_group_label>ActivBPL1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Active Probiotic Bifidobacterium animalis subsp. lactis BPL1 (CECT 8145)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>InactivBPL1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Inactivated probiotic Bifidobacterium animalis subsp. lactis BPL1 (CECT 8145)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Control</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Active Probiotic</intervention_name>
    <description>Product 1: 200 mg maltodextrin and 100 mg of active Bifidobacterium animalis subsp. lactis BPL1 (CECT 8145) (1011 CFU/g),</description>
    <arm_group_label>ActivBPL1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Inactivated probiotic</intervention_name>
    <description>Product 1: 200 mg maltodextrin and 100 mg of Bifidobacterium animalis subsp. lactis BPL1 (CECT 8145) inactivated by heat (1011 CFU/g),</description>
    <arm_group_label>InactivBPL1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Control</intervention_name>
    <description>Placebo: 300 mg maltodextrin.</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults men or women (&gt;18 years old)

          -  Waist circumference ≥102 cm (men) or ≥88 cm (women) and &lt;150cm

          -  Written informed consent provided before the initial screening visit.

        Exclusion Criteria:

          -  Use of antibiotics within 30-days period before the study

          -  Waist circumference other than those specified in inclusion criteria

          -  Body mass index (BMI) ≥ 40 kg/m2

          -  Glucose (fasting state) ≥ 126 mg/dL

          -  Anemia (hemoglobin ≤13 g/dL in men and ≤12 g/dL in women)

          -  Suffer from claustrophobia (to the extent that precludes NMR).

          -  Wear pacemakers, electrical stimulators or cochlear implants (NMR contraindications)

          -  Following a hypocaloric diet and/or receiving pharmacologic treatment for weight loss

          -  Having eating disorders.

          -  Use of medication, antioxidant, or multi-vitamin supplements interfering with the
             study

          -  Chronic gastrointestinal pathology

          -  Being intolerant or suffer from allergy to any of the products of the study.

          -  Pregnant or intending to become pregnant

          -  Being in breastfeeding period.

          -  Chronic alcoholism

          -  Current or past participation in a clinical trial or consumption of a research product
             in the 30 days prior to inclusion in the study.

          -  Failing to follow study guidelines.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rosa Solà, Prof. MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Rovira i Virgili / Hospital Universitari Sant Joan de Reus</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rosa Maria Valls, PhD</last_name>
    <phone>+34 636 944 723</phone>
    <email>estudis@ctns.cat</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Anna Pedret, PhD</last_name>
    <phone>+34 636 944 723</phone>
    <email>estudis@ctns.cat</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Technological Centre of Nutrition and Health (CTNS)</name>
      <address>
        <city>Reus</city>
        <state>Tarragona</state>
        <zip>43204</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rosa Maria Valls, PhD</last_name>
      <phone>+34 636 944 723</phone>
      <email>estudis@ctns.cat</email>
    </contact>
    <investigator>
      <last_name>Anna Pedret, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ignasi Papell-Garcia, BSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://www.ctns.cat</url>
    <description>Technological Centre of Nutrition and Health</description>
  </link>
  <reference>
    <citation>Vaccaro O, Masulli M, Cuomo V, Rivellese AA, Uusitupa M, Vessby B, Hermansen K, Tapsell L, Riccardi G. Comparative evaluation of simple indices of insulin resistance. Metabolism. 2004 Dec;53(12):1522-6.</citation>
    <PMID>15562393</PMID>
  </reference>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 20, 2016</study_first_submitted>
  <study_first_submitted_qc>September 30, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 3, 2016</study_first_posted>
  <last_update_submitted>September 30, 2016</last_update_submitted>
  <last_update_submitted_qc>September 30, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 3, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cardiovascular diseases</keyword>
  <keyword>abdominal visceral fat</keyword>
  <keyword>subcutaneous body fat</keyword>
  <keyword>body weight</keyword>
  <keyword>waist circumference</keyword>
  <keyword>lipid profile</keyword>
  <keyword>insulin resistance</keyword>
  <keyword>glucose metabolism</keyword>
  <keyword>blood pressure</keyword>
  <keyword>inflammation</keyword>
  <keyword>adiponectin</keyword>
  <keyword>leptin</keyword>
  <keyword>metabolomics</keyword>
  <keyword>cardiovascular risk factor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

